WallStreetZenWallStreetZen

NASDAQ: RIGL
Rigel Pharmaceuticals Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Rigel Pharmaceuticals earnings were $364.2M for the trailing 12 months ending Mar 31, 2026, with 863.3% growth year over year. The latest RIGL earnings report on Mar 31, 2026 announced Q1 2026 earnings of $8.7M, down 96.8% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, RIGL reported annual earnings of $367.0M, with 1,999.1% growth.

RIGL past earnings growth

How has RIGL's earnings growth performed historically?

Company
863.33%
Industry
46.31%
Market
92.42%
RIGL's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
RIGL's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Market Performance
RIGL's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

RIGL earnings history

Current Revenue
$299.8M
Current Earnings
$364.2M
Current Profit Margin
121.5%

RIGL Return on Equity

Current Company
147%
Current Industry
-142.1%
Current Market
14.1%
RIGL's Return on Equity (147%)... subscribe to Premium to read more.
High Return on Equity Performance

RIGL Return on Assets

Current Company
99.3%
Current Industry
-13.5%
RIGL is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when RIGL announces earnings.

RIGL Return on Capital Employed

Current Company
31.05%
Current Industry
-9.4%
RIGL has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

RIGL vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
RIGL$131.28M$364.23M+863.33%$20.23
CBIO-$158.55M-$162.08MN/A-$11.82
GYRE$1.33M-$6.36MN/A-$0.08
PROK-$65.81M-$72.29MN/A-$0.53
ARVN-$216.00M-$221.30MN/A-$3.18
View Top Biotech Stocks

Rigel Pharmaceuticals Earnings Reports & History FAQ

What were Rigel Pharmaceuticals's earnings last quarter?

Rigel Pharmaceuticals (NASDAQ: RIGL) reported Q1 2026 earnings per share (EPS) of $0.47, up 26.56% year over year. Total RIGL earnings for the quarter were $8.65 million. In the same quarter last year, Rigel Pharmaceuticals's earnings per share (EPS) was $0.64.

If you're new to stock investing, here's how to buy Rigel Pharmaceuticals stock.

Is Rigel Pharmaceuticals profitable or losing money?

As of the last Rigel Pharmaceuticals earnings report, Rigel Pharmaceuticals is currently profitable. Rigel Pharmaceuticals's net profit (also called net income) for the twelve months ending Mar 31, 2026 was $364.23 million, a 879.7% increase year over year.

What was RIGL's earnings growth in the past year?

As of Rigel Pharmaceuticals's earnings date in Q2 2026, Rigel Pharmaceuticals's earnings has grown 863.33% year over year. This is 817.02 percentage points higher than the US Biotechnology industry earnings growth rate of 46.31%. RIGL earnings in the past year totalled $364.23 million.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.